On January 4, 2026, Ascletis Pharma Inc. (HKEX: 1672), a Hong Kong-listed biotechnology company specializing in metabolic diseases, announced U.S. FDA clearance of its Investigational New Drug (IND) application for a Phase II clinical trial of ASC30 in type 2 diabetes mellitus (T2DM). ASC30 is an in-house discovered oral small molecule glucagon-like peptide-1 receptor (GLP-1R) fully biased agonist, designed for once-daily oral administration or once-monthly to once-quarterly subcutaneous dosing, targeting obesity, diabetes, and related conditions.
The upcoming 13-week Phase II study is a randomized, double-blind, placebo-controlled, multi-center trial across U.S. sites, enrolling about 100 participants with T2DM. Patients will be assigned in a 2:3:3:2 ratio to ASC30 doses of 40 mg, 60 mg, 80 mg, or placebo, with weekly dose titration starting from 1 mg. The primary endpoint is the mean change in HbA1c from baseline at 13 weeks versus placebo. Secondary endpoints include changes in fasting blood glucose and body weight, alongside comprehensive safety and tolerability assessments. Enrollment is slated to begin in the first quarter of 2026.
This milestone follows strong results from a completed 13-week U.S. Phase II trial in 125 obese or overweight participants (NCT07002905), where ASC30 demonstrated dose-dependent placebo-adjusted weight reductions of up to 7.7% (at 60 mg) with no weight loss plateau. Notably, ASC30 exhibited superior gastrointestinal tolerability—vomiting rates roughly half those reported for Lilly’s orforglipron under weekly titration, and a low 4.8% discontinuation rate due to adverse events. No hepatic safety signals were observed.
ASC30’s fully biased agonism avoids β-arrestin recruitment, potentially contributing to its favorable profile. Developed using Ascletis’ proprietary AI-assisted drug discovery and ultra-long-acting platforms, it stands out in a competitive field dominated by peptide-based GLP-1s (e.g., semaglutide) and emerging small molecules like orforglipron.
The global GLP-1 receptor agonist market, valued at over USD 53 billion in 2024, is projected to exceed USD 156 billion by 2030, driven by rising T2DM and obesity prevalence. Oral small molecule options promise improved convenience over injectables. As stated by Founder and CEO Dr. Jinzi Jason Wu, this IND clearance marks a key step in advancing ASC30 toward the vast diabetes treatment landscape, enhancing patient access to innovative, tolerable therapies.
